BEIGENE (06160.HK) announced that according to US GAAP, the company expects to achieve positive operating income for the full ...

BeiGene (ONC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

BeiGene ADR is working on a consolidation with a 248.16 entry. See if the stock can clear the breakout price in volume at ...

BeiGene stock just hit that mark, with a jump from 69 to 84 Wednesday. Is BeiGene Stock A Buy? BeiGene stock reclaimed its 50 ...

BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.26 million.

Analyst Jill Wu of CMB International Securities maintained a Buy rating on BeiGene (ONC – Research Report), boosting the price target to ...

StockNews.com initiated coverage on shares of BeiGene (NASDAQ:BGNE – Free Report) in a research note issued to investors on Sunday. The brokerage issued a hold rating on the stock. Several other ...

Dealmakers at BeiGene, Brii Biosciences and Ideaya Biosciences had a busy end to the year, sharing news of agreements for antibody-drug conjugates (ADCs) and other assets in the final few days of ...

David Li, an analyst from Bank of America Securities, maintained the Hold rating on BeiGene (ONC – Research Report). The associated price ...

This executive interview, sponsored by BeiGene, is with Jan-Henrik Terwey, Vice President, Medical Affairs Europe at BeiGene.

BeiGene has won approval from the US Food and Drug Administration for its PD-1 inhibitor Tevimbra (tislelizumab) in combination with chemotherapy to treat advanced gastric or gastroesophageal ...